iTonic Holdings Ltd. (ITOC) AI Stock Analysis
ITOC AI stock analysis summary
AI ResearchiTonic Holdings Ltd. (ITOC) is a medical devices provider developing brachytherapy software and treatment devices. In FY2025, the company generated $523,031 in revenue but recorded a net loss of -$5.1M. As of June 30, 2026, it held $2.2M in cash and short-term investments against total debt of $244,457.
- Market cap
- $28.1M
- Revenue (TTM)
- $556,430
- P/E
- —
- 1Y return
- -60.3% S&P 500 16.8%
- Avg. target
- —
Bull case
- Quarterly revenue expanded by 49.5% year-over-year in the period ending June 30, 2026.
- The company maintains a healthy liquidity cushion with a current ratio of 17.39 and net cash of $2.0M as of June 30, 2026.
- Shares trade at a price-to-book ratio of 0.9x relative to shareholders' equity of $23.6M.
Bear case
- Operating losses escalated sharply in FY2025, reaching an operating margin of -991.7% and a net loss of -$5.1M.
- Cash burn remains substantial, evidenced by negative free cash flow of -$3.2M in FY2025.
- The stock trades at an elevated price-to-sales multiple of 50.5x compared to the US-listed Healthcare median of 4.1x.
What iTonic does
iTonic Holdings Ltd., formerly known as Pheton Holdings Ltd, is a Beijing-based healthcare solutions provider founded in 1998 that operates as a subsidiary of ZJW (BVI) LTD. With 7 employees, the company develops and commercializes treatment software and devices used for brachytherapy. Its radioactive particle implantation technology places radioactive sources inside cancer patients to destroy cancer cells and shrink tumors. iTonic offers FTTPS, a proprietary treatment planning system for malignant tumors that determines target volume, prescription dose, and dose limitations to safeguard organs at risk while delivering accurate dose distribution plans.
Growth and profitability
Between FY2021 and FY2025, revenue contracted at a 4-year compound annual growth rate of -7.1%, declining from $702,776 in FY2021 to $448,196 in FY2024 before rising 16.7% to $523,031 in FY2025. Gross margin compressed from 84.1% in FY2021 to 62.6% in FY2025. Profitability dropped significantly as operating margin shifted from 19.6% in FY2021 to -991.7% in FY2025, driven by research and development expenses rising to $459,135. Net income worsened from $192,462 in FY2021 to -$5.1M in FY2025. For the trailing twelve months ended June 30, 2026, revenue stood at $556,430 with quarterly revenue growth of 49.5% year-over-year, while operating margin was -5036.1% and diluted earnings per share was -$4.22.
Balance sheet and cash flow
As of June 30, 2026, iTonic reported $2.2M in cash and short-term investments alongside total debt of $244,457, resulting in net cash of $2.0M. Total assets reached $26.6M against shareholders' equity of $23.6M, yielding a debt-to-equity ratio of 0.01 and a current ratio of 17.39. In FY2025, operating cash flow was -$3.2M and free cash flow was -$3.2M. Capital expenditures totaled $3,806 during FY2025, reflecting minimal spending on fixed assets.
Valuation and performance
With a market capitalization of $28.1M and an enterprise value of $2.7M, iTonic trades at a price-to-sales multiple of 50.5x, well above the 4.1x median of its US-listed Healthcare peers. Its enterprise value-to-revenue multiple is 5.1x, while its price-to-book ratio is 0.9x. The stock has underperformed broader markets, falling 60.3% over the past year compared to a 16.8% gain for the S&P 500 (SPY). ITOC shares closed at $3.84 on October 16, 2026, trading 29.0% below their 200-day moving average and showing high volatility with a beta of 2.79.
What analysts expect
There are no published analyst ratings, consensus price targets, or earnings estimates available for iTonic Holdings Ltd. Following its 2024 initial public offering, the company has maintained limited institutional following, with institutional ownership at 0.3% and insider ownership at 1.8%. The stock closed at $3.84 on October 16, 2026, which is near the lower end of its 52-week trading range of $3.42 to $18.40. Without forward earnings projections, investors must evaluate historical operating results and its market capitalization of $28.1M directly.
Key risks and what to watch
- With cash and short-term investments of $2.2M, the FY2025 cash burn of -$3.2M poses a severe liquidity risk without additional financing.
- Gross margin contracted from 84.1% in FY2021 to 62.6% in FY2025, indicating rising production costs relative to sales.
- High market volatility is reflected in a beta of 2.79 and a 1-year stock decline of 60.3%.
- Revenue long-term trend remains pressured, having posted a 4-year CAGR of -7.1% between FY2021 and FY2025.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this ITOC AI stock analysis
This page is an AI-written research summary of iTonic Holdings Ltd. (ITOC). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: ITOC income statement, ITOC balance sheet, ITOC key metrics, ITOC chart. See the ITOC stock overview for the latest quote and news.
ITOC AI stock analysis FAQ
What does iTonic Holdings Ltd. do?
Founded in 1998, iTonic Holdings Ltd. develops and commercializes brachytherapy software and devices, including its proprietary FTTPS treatment planning system used for cancer treatment.
Does iTonic Holdings Ltd. pay a dividend?
No, iTonic Holdings Ltd. does not pay a dividend.
How much debt does iTonic have?
As of June 30, 2026, iTonic reported total debt of $244,457 against cash and short-term investments of $2.2M, leaving the company with net cash of $2.0M.
What is iTonic's valuation compared to peers?
iTonic trades at a price-to-sales multiple of 50.5x and an enterprise value-to-revenue multiple of 5.1x, compared to the median price-to-sales ratio of 4.1x for its US-listed Healthcare peers.